Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 11/2003

01-11-2003 | Review Article

Non-Hodgkin's lymphoma in the elderly

A review with emphasis on elderly patients, geriatric assessment, and future perspectives

Authors: E. Maartense, H. C. Kluin-Nelemans, E. M. Noordijk

Published in: Annals of Hematology | Issue 11/2003

Login to get access

Abstract

With rising age the incidence of non-Hodgkin's lymphoma (NHL), together with the fact that the proportion of people older than 65 years in Western populations will double during the next 40 years, poses the challenge to adequately meet the needs of elderly patients. After a general introduction on cancer in the elderly, a review is given concerning aspects of epidemiology and prognostic factors of NHL. Therapeutic strategies, including the use of hematopoietic growth factors, for the elderly with aggressive NHL are discussed. The future role for so-called comprehensive geriatric assessment (CGA) to appropriately determine treatment possibilities is emphasized. Much scientific work has to be performed before the true value of CGA instruments can be acknowledged. Screening instruments are discussed and the role for specially trained oncology nurses in the assessment process is stipulated.
Literature
1.
Balducci L, Extermann M (2001) A practical approach to the older patient with cancer. Curr Probl Cancer 25:5-76
2.
Wymenga ANM, Slaets JPJ, Sleijfer DTh (2001) Treatment of cancer in old age, shortcomings and challenges. Neth J Med 59:259–266CrossRefPubMed
3.
Visser O, Coebergh JWW, Dijck JAAM van, Siesling S (eds) (2002) Incidence of cancer in the Netherlands 1998. Vereniging van Integrale Kankercentra, Utrecht
4.
Extermann M, Balducci L, Lyman GH (2000) What threshold for adjuvant therapy in older breast cancer patients? J Clin Oncol 18:1709–1717PubMed
5.
Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582–1587PubMed
6.
Repetto L, Fratino L, Audisio RA, Venturino A, Gianni W, Vercelli M, Parodi S, Dal Lago D, Gioia F, Monfardini S, Aapro MS, Serraino D, Zagonel V (2002) Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 20:494–502CrossRefPubMed
7.
McCorkle R, Strumpf NE, Nuamah IF, Adler DC, Cooley ME, Jepson C, Lusk EJ, Torosian M (2000) A specialized home care intervention improves survival among older post-surgical cancer patients. J Am Geriatr Soc 48:1707–1713PubMed
8.
Dijck JAAM van, Coebergh JWW, Siesling S, Visser O (eds) (2002) Trends of cancer in the Netherlands 1989–1998. Vereniging van Integrale Kankercentra, Utrecht
9.
d'Amore F, Brincker H, Christensen BE, Thorling K, Pedersen M, Lanng Nielsen J, Sandberg E, Pedersen NT, Sørensen E (1992) Non-Hodgkin's lymphoma in the elderly. Ann Oncol 3:379–386PubMed
10.
Krol ADG, Cessie le S, Snijder S, Kluin-Nelemans JC, Kluin PhM, Noordijk EM (2003) Non-Hodgkin's lymphoma in The Netherlands: results from a population-based registry. Leuk Lymphoma 44:451–458PubMed
11.
Maartense E, Hermans J, Kluin-Nelemans JC, Kluin PhM, Deijk van WA, Snijder S, Wijermans PW, Noordijk EM (1998) Elderly patients with non-Hodgkin's lymphoma: population-based results in the Netherlands. Ann Oncol 9:1219–1227
12.
Maartense E, Kluin-Nelemans JC, Cessie le S, Kluin PhM, Snijder S, Noordijk EM (2000) Different age limits for elderly patients with indolent and aggressive non-Hodgkin lymphoma and the role of relative survival with increasing age. Analysis of a population-based non-Hodgkin lymphoma registry. Cancer 89:2667–2676CrossRefPubMed
13.
Cartwright R, Brincker H, Carli PM, Clayden D, Coebergh JW, Jack A, McNally R, Morgan G, Sanjose de S, Tumino R, Vornanen M (1999) The rise in incidence of lymphomas in Europe 1985–1992. Eur J Cancer 35:627–633CrossRefPubMed
14.
Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ (2002) Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst 94:1204–1210CrossRefPubMed
15.
Carli PM, Coebergh JWW, Verdecchia A, the EUROCARE Working Group (1998) Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 34:2253–2263CrossRef
16.
The International non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987–994PubMed
17.
Lopez-Guillermo A, Montserrat E, Bosch F, Terol MJ, Campo E, Rozman C (1994) Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 12:1343–1348PubMed
18.
Hermans J, Krol ADG, Groningen van K, Kluin PhM, Kluin-Nelemans JC, Kramer MHH, Noordijk EM, Ong F, Wijermans PW (1995) International prognostic index for aggressive non-Hodgkin's lymphoma is valid for all malignancy grades. Blood 86:1460–1463PubMed
19.
Bastion Y, Coiffier B (1994) Is the international prognostic index for aggressive lymphoma patients useful for follicular lymphoma patients (editorial)? J Clin Oncol 12:1340–1342PubMed
20.
Leonard RCF, Hayward RL, Prescott RJ, Wang J-X (1991) The identification of discrete prognostic groups in low grade non-Hodgkin's lymphoma. Ann Oncol 2:655–662
21.
Cameron DA, Leonard RCF, Mao J-H, Prescott RJ (1993) Identification of prognostic groups in follicular lymphoma. Leuk Lymphoma 10:89–99PubMed
22.
Romaguera JE, McLaughlin P, North L, Dixon D, Silvermintz KB, Garnsey LA, Velasquez WS, Hagemeister FB, Cabanillas F (1991) Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model. J Clin Oncol 9:762–769PubMed
23.
Rodriguez J, McLaughlin P, Hagemeister FB, Fayad L, Rodriguez MA, Santiago M, Hess M, Romaguera J, Cabanillas F (1999) Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 93:2202–2207PubMed
24.
Decaudin D, Lepage E, Brousse N, Brice P, Harousseau JL, Belhadj K, Tilly H, Michaux L, Chèze S, Coiffier B, Solal-Céligny Ph (1999) Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients—a study of the Groupe d'Etude des Lymphomes de l' Adulte. J Clin Oncol 17:2499–2505PubMed
25.
Federico M, Vitolo U, Zinzani PL, Chisesi T, Clò V, Bellesi G, Maganoli M, Liberati M, Boccomini C, Niscola P, Pavone V, Cuneo A, Santini G, Brugiatelli M, Baldini L, Rigacci L, Resegotti L (2000) Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood 95:783–789PubMed
26.
Maartense E, Cessie le S, Kluin-Nelemans JC, Kluin PhM, Snijder S, Wijermans PW, Noordijk EM (2002) Age-related differences among patients with follicular lymphoma and the importance of prognostic scoring systems: analysis from a population-based non-Hodgkin's lymphoma registry. Ann Oncol 13:1275–1284
27.
The Non-Hodgkin's Lymphoma Classification Project (1997) Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. Ann Oncol 8:973–978
28.
Drillenburg P, Wielenga VJM, Kramer MHH, Krieken van JHJM, Kluin-Nelemans JC, Hermans J, Heisterkamp S, Noordijk EM, Kluin PhM, Pals ST (1999) CD44 expression predicts disease outcome in localized large B-cell lymphoma. Leukemia 13:1448–1455CrossRefPubMed
29.
Shipp MA (1994) Prognostic factors in aggressive non-Hodgkin's lymphoma: who has "high-risk" disease? Blood 83:1165–1173PubMed
30.
Montserrat E (2001) Prognostic factors in aggressive lymphoma: the contribution of novel biological markers. Ann Hematol 80: B42-B44PubMed
31.
Kluin PhM (1994) Bcl-6 in lymphoma—sorting out a wastebasket (editorial)? N Engl J Med 331:116–118CrossRefPubMed
32.
Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) (2001) World Health Organization Classification of tumours. Pathology and genetics of haematopoietic and lymphoid tissues. IARC Press, Lyon
33.
Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyes F, Gaulard Ph (1996) Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Blood 87:265–272PubMed
34.
Hill ME, MacLennan KA, Cunningham DC, Vaughan Hudson B, Burke M, Clarke P, Di Stefano F, Anderson L, Vaughan Hudson G, Mason D, Selby P, Linch DC (1996) Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma; a British National Lymphoma Investigation study. Blood 88:1046–1051PubMed
35.
Kramer MHH, Hermans J, Parker J, Krol ADG, Kluin-Nelemans JC, Haak HL, Groningen van K, Krieken van JHJM, Jong de J, Kluin PhM (1996) Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 14:2131–2138PubMed
36.
Gascoyne RD, Adomat SA, Krajewski S, Krajewska M, Horsman DE, Tolcher AW, O'Reilly SE, Hoskins P, Coldman AJ, Reed JC, Connors JM (1997) Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244–251PubMed
37.
Kramer MHH, Hermans J, Wijburg E, Philippo K, Geelen E, Krieken van JHJM, Jong de D, Maartense E, Schuuring E, Kluin PhM (1998) Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 92:3152–3162PubMed
38.
Winter JN (1999) Prognostic indicators in diffuse, aggressive non-Hodgkin's lymphomas: regulators of growth fraction and programmed cell death. Semin Oncol 26 [Suppl 14]:26–33
39.
Gascoyne RD (1997) Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma. Hematol Oncol Clin North Am 11:847–862PubMed
40.
Piris MA, Pezella F, Martinez-Montero JC, Orradre JL, Villuendas R, Sanchez-Beato M, Cuena R, Cruz MA, Martinez B, Garrido MC, Gatter K, Aiello A, Delia D, Giardini R, Rilke F (1994) P53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer 69:337–341PubMed
41.
Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K, Saito H, Hotta T (1997) Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 337:529–534
42.
Leroy K, Haioun C, Lepage E, Le Métayer N, Berger F, Labouyrie E, Meignin V, Petit B, Bastard C, Salles G Gisselbrecht C, Reyes F, Gaulard Ph (2002) P53 gene mutations are associated with poor survival in low and low-intermediate risk diffuse large B-cell lymphomas. Ann Oncol 13:1108–1115
43.
Maartense E, Kramer MHH, Cessie le S, Kluin-Nelemans JC, Kluin PhM, Snijder S, Noordijk EM (2003) Lack of prognostic significance of BCL2 and p53 protein overexpression in elderly patients with diffuse large B-cell non-Hodgkin's lymphoma: results from a population-based non-Hodgkin's lymphoma registry. Leuk Lymphoma, in press
44.
Alizadeh AA, Eisen MB, Davis ER, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson Jr J, Lu L, Lewis DB, Tibshirani R, Sherloc, G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMed
45.
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirow J, Neuberg DS, Lander ES, Aster JC, Golub TR (2002) Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nature Med 8:68–74CrossRefPubMed
46.
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink K, Smeland EB, Staudt LM (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med 346:1937–1947
47.
Maazen RWM van der, Noordijk EM, Thomas J, Raemaekers JMM, Meerwaldt JH (1998) Combined modality treatment is the treatment of choice for stage I/IE intermediate and high grade non-Hodgkin's lymphomas. Radiother Oncol 49:1-7CrossRefPubMed
48.
Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan ThM, LeBlanc M, Carlin S, Chase E, Fisher RI (1998) Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high grade non-Hodgkin's lymphoma. N Engl J Med 339:21–26PubMed
49.
Bonnet C, Fillet G, Mounier N, Thieblemont C, Fermé C, Quesnel B, Martin C, Blanc M, Conroy Th, Penny AM, Petrella T, Reyes F (2002) Radiotherapy is unnecessary in elderly patients with localized aggressive non-Hodgkin's lymphoma: results of the LNH 93–4 study. Ann Oncol 13 [Suppl 2]:A079
50.
51.
Zachariah B, Balducci L, Venkattaramanabalaji GV, Casey L, Greenberg HM, DelRegato JA (1997) Radiotherapy for cancer patients aged 80 and older: a study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 39:1125–1129CrossRefPubMed
52.
Vose JM, Armitage JO, Weisenburger DD, Bierman PhJ, Sorensen S, Hutchins M, Moravec DF, Howe D, Dowling MD, Mailliard J, Steven Johnson P, Pevnick W, Packard WM, Okerbloom J, Thompson RF, Langdon Jr RM, Soori G, Peterson C (1988) The importance of age in survival of patients treated with chemotherapy for aggressive non-Hodgkin's lymphoma. J Clin Oncol 6:1838–1844PubMed
53.
Sonneveld P, Michiels JJ (1990) Full dose chemotherapy in elderly patients with non-Hodgkin's lymphoma: a feasibility study using a mitoxantrone containing regimen. Br J Cancer 62:105–108PubMed
54.
O'Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P, Stuart DS (1993) In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 11:2250–2257PubMed
55.
Martelli M, Guglielmi C, Coluzzi S, Avvisati G, Amadori S, Giovannini M, Torromeo C, Mandelli F (1993) P-VABEC: a prospective study of a new weekly chemotherapy regimen for elderly aggressive non-Hodgkin's lymphoma. J Clin Oncol 11:2362–2369PubMed
56.
Bertini M, Freilone R, Vitolo U, Botto B, Pizzuti M, Gavarotti P, Levis A, Orlandi E, Orsucci L, Pini M, Rota Scalabrini D, Salvi F, Secondo V, Todeschini G, Viero P, Volta C, Resegotti L (1994) P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 5:895–900PubMed
57.
Tirelli U, Zagonel V, Sorio R, Errante D, Talamini R, Carbone A, Monfardini S (1994) Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients. Semin Hematol 31 [Suppl 3]:13–22
58.
Guerci A, Lederlin P, Reyes F, Bordessoule D, Sebban C, Tilly H, Kerneis Y, Biron P, Gisselbrecht C, Herbrecht R, Coiffier B (1996) Effect of granulocyte colony-stimulating factor administration in elderly patients with aggressive non-Hodgkin's lymphoma treated with a pirarubicin-containing chemotherapy regimen. Ann Oncol 7:966–969
59.
Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E, Gentilini P, Guardigni L, Gobbi M, Fattori PP, Falini B, Lauta VM, Bendandi M, Gherlinzoni F, De Renzo A, Zaja F, Mazza P, Volpe E, Bocchia M, Aitini E, Tabanelli M, Leone G, Tura S (1999) Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 94:33–38PubMed
60.
Zinzani PL, Gherlinzoni F, Storti S, Zaccaria A, Pavone E, Moretti L, Gentilini P, Guardigni L, De Renzo A, Fattori PP, Falini B, Lauta VM, Mannin D, Zaja F, Mazza P, Volpe E, Lauria F, Aitini E, Ciccone F, Tani M, Stefoni V, Alinari L, Baccarini M, Tura S (2002) Randomized trial of 8-week versus 12-week VNCOP-B plus G-CSF regimens as front-line treatment in elderly aggressive non-Hodgkin's lymphoma patients. Ann Oncol 13:1364–1369
61.
Kouroukis CT, Browman GP, Esmail R, Meyer RM (2002) Chemotherapy for older patients with newly diagnosed advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 136:144–152
62.
Balducci L, Yates J (2000) General guidelines for the management of older patients with cancer. Oncology 14:221–227PubMed
63.
Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PhA, Schiffer ChA, Smith ThJ, Somlo G, Wade JC, Wade III JL, Winn RJ, Wozniak AJ, Somerfield MR (2000) 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 18:3558–3585PubMed
64.
Zinzani PL, Pavone E, Storti S, Moretti L, Fattori PP, Guardigni L, Falini B, Gobbi M, Gentilini P, Lauta VM, Bendandi M, Gherlinzoni F, Magagnoli M, Venturi S, Aitini E, Tabanelli M, Leone G, Liso V, Tura S (1997) Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade nonHodgkin's lymphoma. Blood 89:3974–3979PubMed
65.
Ösby E, Hagberg H, Kvalöy S, Teerenhovi L, Anderson H, Cavallin-Stahl E, Holte H, Myhre J, Pertovaara H, Björkhom M (2003) CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim: results of a Nordic Lymphoma Group randomized trial. Blood 101:3840–3848CrossRefPubMed
66.
Doorduijn JK, Holt B van der, Buijt I, Hem van der KG, Imhoff van GW, Kramer MHH, Oers van MHJ, Ossenkoppele GJ, Schaafsme MR, Verdonck LF, Verhoef GEG, Steijaert MMC, Löwenberg B, Sonneveld P (2002) Prophylactic granulocyte-colony stimulating factor (G-CSF) added to CHOP in the treatment of elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Final results of a multicenter phase 3 study. Ann Oncol 13 [Suppl 2]:A083
67.
Pfreundschuh M, Trümper L, Kloess M, Schmitz N, Glass B, Schmits R, Engert A, Rudolph C, Illiger J, Hossfeld D, Loeffler M (2002) 2-Weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin's lymphoma (NHL) >60 years of age. Ann Oncol 13 [Suppl 2]:A081
68.
Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Neste van den E, Salles G, Gaulard Ph, Reyes F, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 346:235–242PubMed
69.
Mounier N, Briere J, Gisselbrecht C, Gaulard PH, Lederlin P, Sebban C, Bosly A, Morel P, Tilly H, Bouabdallah R, Reyes F, Coiffier B (2002) Rituximab plus CHOP (R-CHOP) in the treatment of elderly patients with diffuse large B-cell lymphoma (DLBCL) overcomes Bcl2-associated chemotherapy resistance. Blood 100:A603
70.
Pettengell R, Linch D (2003) Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 121:44–48PubMed
71.
72.
Rijke JM de, Schouten LJ, Schouten HC, Jager JJ, Koppejan AG, Brandt van den PA (1996) Age-specific differences in the diagnostics and treatment of cancer patients aged 50 years and older in the province of Limburg, the Netherlands. Ann Oncol 7:677–685PubMed
73.
Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 [Suppl 5]:S75-S88
74.
Nathwani BN, Harris NL, Weisenburger D, Isaacson PG, Piris MA, Berger F, Muller-Hermelink HK, Swerdlow SH (2001) Follicular lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon, pp 162–167
75.
Peters FPJ, Lalisang RI, Fickers MMF, Erdkamp FLG, Wils JAJM, Houben SJG, Wals J, Schouten HC (2001) Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study. Ann Hematol 80:155–159CrossRefPubMed
76.
Neilly IJ, Ogston M, Bennett B, Dawson AA (1995) High grade non-Hodgkin's lymphoma in the elderly—12 year experience in the Grampian region of Scotland. Hematol Oncol 13:99–106PubMed
77.
Armitage JO, Potter JF (1984) Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 32:269–273PubMed
78.
Dixon DO, Neilan B, Jones SE, Lipschitz DA, Miller ThP, Grzea PN, Wilson HE (1986) Effect of age on therapeutic outcome in advanced diffuse histiocytic lymphoma: the Southwest Oncology Group experience. J Clin Oncol 4:295–305PubMed
79.
Coiffier B (1994) What treatment for elderly patients with aggressive lymphoma? Ann Oncol 5:873–875PubMed
80.
Naeim A, Reuben D (2001) Geriatric syndromes and assessment in older cancer patients. Oncology 15:1567–1580PubMed
81.
Serraino D, Fratino L, Zagonel V, for the GIOGer Study Group (2001) Prevalence of functional disability among elderly patients with cancer. Crit Rev Oncol Hematol 39:269–273CrossRefPubMed
82.
Zagonel V (2001) Importance of a comprehensive geriatric assessment in older cancer patients. Eur J Cancer 37 [Suppl 7]:S229–S233
83.
Stuck AE, Siu AL, Wieland GD (1993) Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet 342:1032–1036PubMed
84.
Cohen HJ, Feussner JR, Weinberger M, Carnes M, Hamdy RC, Hsieh F, Phibbs C, Lavori Ph (2002) A controlled trial of inpatient and outpatient geriatric evaluation and management. N Engl J Med 346:905–912CrossRefPubMed
85.
Ingram SS, Seo PH, Martell RE, Clipp EC, Doyle ME, Montana GS, Cohen HJ (2002) Comprehensive assessment of the elderly cancer patient: the feasibility of self-report methodology. J Clin Oncol 20:770–775CrossRefPubMed
86.
Freyer G, Le Rol A, Weber B,Provencal J, Ganem G, Jacquin J, Lavau-Denes S, Gisserot O, Flesch M, Paraiso D (2002) Geriatric evaluation and feasibility of platin-based first-line chemotherapy in elderly patients with advanced ovarian cancer. Proc ASCO 2002:A1432
87.
Zagonel V, Fratino L, Piselli P, Milan I, La Conca G, Serraino D, Monfardini S (2002) The comprehensive geriatric assessment predicts mortality among elderly cancer patients. Proc ASCO 2002:A1458
88.
Colussi AM, Mazzer L, Candotto D, De Biasi M, De Lorenzi L, Pin I, Pusiol N, Romanin C, Zamattio V (2001) The elderly cancer patient: a nursing perspective. Crit Rev Oncol Hematol 39:235–245CrossRefPubMed
89.
Lachs MS, Feinstein AR, Cooney Jr. LM, Drickamer MA, Marottoli RA, Pannill FC, Tinetti ME (1990) A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 112:699–706PubMed
90.
Folstein MF, Folstein SE, McHugh PR (1975) Mini mental state. A practical method for grading the cognitive state of patients for the clinicians. J Psychiatr Res 12:189–198PubMed
91.
Brink TL, Yesavage JA, Lum O, Hevesuma PH, Adey M, Rose TL (1982) Screening test for geriatric depression. Clin Gerontol 1:37–44
92.
Katz S, Akpom CA (1976) A measure of primary sociological function. Int J Health Serv 6:493–507PubMed
93.
Lawton MP, Moss M, Fulcomer M, Kleban MH (1982) A research and service oriented multilevel assessment instrument. J Gerontol 37:91–99PubMed
94.
Extermann M (1999) Assessment of the older cancer patient. In: Perry MC (ed) American Society of Clinical Oncology 1999 educational book. Lippincott Williams & Wilkins, Baltimore, pp 353–360
Metadata
Title
Non-Hodgkin's lymphoma in the elderly
A review with emphasis on elderly patients, geriatric assessment, and future perspectives
Authors
E. Maartense
H. C. Kluin-Nelemans
E. M. Noordijk
Publication date
01-11-2003
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 11/2003
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-003-0722-1

Other articles of this Issue 11/2003

Annals of Hematology 11/2003 Go to the issue

Original Article

Mutations of the 5′ noncoding region of the BCL-6 gene in primary bone lymphomas

Letter to the Editor

Demyelination in the brain as a paraneoplastic disorder: candidates include some cases of leukemia and non-Hodgkin's lymphoma

Original Article

Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors

Letter to the Editor

Late relapse of non-Hodgkin's lymphoma after a 28-year disease-free interval: an unusual case

Case Report

Life-threatening thrombotic thrombocytopenic purpura (TTP) in a patient with sickle cell-hemoglobin C disease

Letter to the Editor

Severe factor X deficiency treated with heparin-added prothrombin complex concentrate
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits